Document Detail

Predictors of urinary morbidity in cs-131 prostate brachytherapy implants.
MedLine Citation:
PMID:  20888139     Owner:  NLM     Status:  In-Data-Review    
PURPOSE: Cesium-131 is a newer radioisotope being used in prostate brachytherapy (PB). This study was conducted to determine the predictors of urinary morbidity with Cs-131 PB.
METHODS AND MATERIALS: A cohort of 159 patients underwent PB with Cs-131 at our institution and were followed by using Expanded Prostate Cancer Index Composite (EPIC) surveys to determine urinary morbidity over time. EPIC scores were obtained preoperatively and postoperatively at 2 and 4 weeks, and 3 and 6 months. Different factors were evaluated to determine their individual effect on urinary morbidity, including patient characteristics, disease characteristics, treatment, and dosimetry. Multivariate analysis of covariance was carried out to identify baseline determinants affecting urinary morbidity. Factors contributing to the need for postoperative catheterization were also studied and reported.
RESULTS: At 2 weeks, patient age, dose to 90% of the organ (D90), bladder neck maximum dose (D(max)), and external beam radiation therapy (EBRT) predicted for worse function. At 4 weeks, age and EBRT continued to predict for worse function. At the 3-month mark, better preoperative urinary function, preoperative alpha blockers, bladder neck D(max), and EBRT predicted for worse urinary morbidity. At 6 months, better preoperative urinary function, preoperative alpha blockers, bladder neck D(max), and EBRT were predictive of increased urinary problems. High bladder neck D(max) and poor preoperative urinary function predicted for the need for catheterization.
CONCLUSIONS: The use of EBRT plus Cs-131 PB predicts for worse urinary toxicity at all time points studied. Patients should be cautioned about this. Age was a consistent predictor of worsened morbidity immediately following Cs-131 PB, while bladder D(max) was the only consistent dosimetric predictor. Paradoxically, patients with better preoperative urinary function had worse urinary morbidity at 3 and 6 months, consistent with recently published literature.
Ryan P Smith; Heather A Jones; Sushil Beriwal; Abhay Gokhale; Ronald Benoit
Related Documents :
25055209 - Neural network analysis of different segmentation strategies of nerve fiber layer asses...
12478599 - Video urodynamics using transrectal ultrasonography for lower urinary tract symptoms in...
3617259 - Tubed vesicostomy for tetraplegics.
17681969 - Sublingual oxybutynin reduces postoperative pain related to indwelling bladder catheter...
6695949 - Is the clean-catch midstream void procedure necessary for obtaining urine culture speci...
3735539 - The impact of the artificial urinary sphincter in the neurogenic bladder on the upper u...
17643619 - Aortic enlargement and late reoperation after repair of acute type a aortic dissection.
14734969 - The external fixator: a tool for evaluation of complex low back pain problems.
16430599 - Does wait-list size at registration influence time to surgery? analysis of a population...
Publication Detail:
Type:  Journal Article     Date:  2010-10-01
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  81     ISSN:  1879-355X     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-10-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  745-50     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current role of selective internal irradiation with yttrium-90 microspheres in the management of hep...
Next Document:  Proton Beam Therapy of Stage II and III Non-Small-Cell Lung Cancer.